PATIENT-REPORTED AND QUALITY OF LIFE OUTCOMES FROM MYCARING, A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PHASE 3 TRIAL OF ROZANOLIXIZUMAB IN GENERALISED MYASTHENIA GRAVIS

被引:0
|
作者
Habib, Ali A. [1 ]
Druzdz, Artur [2 ]
Grosskreutz, Julian [3 ]
Kaminski, Henry [4 ]
Mantegazza, Renato [5 ]
Sacconi, Sabrina [6 ]
Utsugisawa, Kimiaki [7 ]
Vissing, John [8 ]
Vu, Tuan [9 ]
Morel, Thomas [10 ]
Boehnlein, Marion [11 ]
Woltering, Franz [11 ]
Bozorg, Ali [12 ]
Gayfieva, Maryam [13 ]
Bril, Vera [14 ]
机构
[1] Univ Calif Irvine, Orange, CA 92668 USA
[2] Municipal Hosp Poznan, Poznan, Poland
[3] Univ Lubeck, Lubeck, Germany
[4] George Washington Univ, Med Ctr, Washington, DC 20037 USA
[5] Fdn IRCCS Ist Neurol Carlo Besta, Milan, Italy
[6] CHU Nice, Nice, France
[7] Hanamaki Gen Hosp, Hanamaki, Japan
[8] Univ Copenhagen, Rigshosp, Copenhagen, Denmark
[9] Univ S Florida, Morsani Coll Med, Tampa, FL 33620 USA
[10] UCB Pharma, Brussels, Belgium
[11] UCB Pharma, Monheim, Germany
[12] UCB Pharma, Morrisville, NC USA
[13] UCB Pharma, Slough, Berks, England
[14] Univ Hlth Network, Toronto, ON, Canada
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
引用
收藏
页码:S19 / S20
页数:2
相关论文
共 50 条
  • [1] Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
    Bril, Vera
    Druzdz, Artur
    Grosskreutz, Julian
    Habib, Ali A.
    Mantegazza, Renato
    Sacconi, Sabrina
    Utsugisawa, Kimiaki
    Vissing, John
    Vu, Tuan
    Boehnlein, Marion
    Bozorg, Ali
    Gayfieva, Maryam
    Greve, Bernhard
    Woltering, Franz
    Kaminski, Henry J.
    [J]. LANCET NEUROLOGY, 2023, 22 (05): : 383 - 394
  • [2] EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY (MYCARING)
    Bril, Vera
    Druzdz, Artur
    Grosskreutz, Julian
    Habib, Ali A.
    Mantegazza, Renato
    Sacconi, Sabrina
    Utsugisawa, Kimiaki
    Vissing, John
    Vu, Tuan
    Boehnlein, Marion
    Woltering, Franz
    Bozorg, Ali
    Gayfieva, Maryam
    Kaminski, Henry
    [J]. MUSCLE & NERVE, 2022, 65 : S35 - S35
  • [3] OUTCOMES FROM RAISE: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PHASE 3 TRIAL OF ZILUCOPLAN IN GENERALIZED MYASTHENIA GRAVIS
    Howard, James F., Jr.
    Genge, Angela
    Hussain, Yessar
    Kaminski, Henry J.
    Mantegazza, Renato
    Utsugisawa, Kimiaki
    Vu, Tuan
    Brock, Melissa
    Boroojerdi, Babak
    Vanderkelen, Mark
    de la Borderie, Guillemette
    Duda, PetraW
    Leite, M. Isabel
    [J]. MUSCLE & NERVE, 2022, 65 : S34 - S35
  • [4] Use of Patient-Reported Outcomes in Randomized, Double-Blind, Placebo-Controlled Clinical Trials
    Dinan, Michaela A.
    Compton, Kate L.
    Dhillon, Jatinder K.
    Hammill, Bradley G.
    DeWitt, Esi Morgan
    Weinfurt, Kevin P.
    Schulman, Kevin A.
    [J]. MEDICAL CARE, 2011, 49 (04) : 415 - 419
  • [5] ROZANOLIXIZUMAB IN GENERALIZED MYASTHENIA GRAVIS: RESPONDER ANALYSES FROM THE RANDOMIZED PHASE 3 MYCARING STUDY
    Bril, Vera
    Druzdz, Artur
    Grosskreutz, Julian
    Habib, Ali
    Mantegazza, Renato
    Sacconi, Sabrina
    Utsugisawa, Kimiaki
    Vissing, John
    Vu, Tuan
    Boehnlein, Marion
    Bozorg, Ali
    Gayfieva, Maryam
    Woltering, Franz
    Kaminski, Henry
    [J]. MUSCLE & NERVE, 2022, 66 : S112 - S112
  • [6] Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study
    Habib, Ali A.
    Sacconi, Sabrina
    Antonini, Giovanni
    Cortes-Vicente, Elena
    Grosskreutz, Julian
    Mahuwala, Zabeen K.
    Mantegazza, Renato
    Pascuzzi, Robert M.
    Utsugisawa, Kimiaki
    Vissing, John
    Vu, Tuan
    Wiendl, Heinz
    Boehnlein, Marion
    Greve, Bernhard
    Woltering, Franz
    Bril, Vera
    [J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2024, 17
  • [7] Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis
    Bril, Vera
    Szczudlik, Andrzej
    Vaitkus, Antanas
    Rozsa, Csilla
    Kostera-Pruszczyk, Anna
    Hon, Petr
    Bednarik, Josef
    Tyblova, Michaela
    Koehler, Wolfgang
    Toomsoo, Toomas
    Nowak, Richard J.
    Mozaffar, Tahseen
    Freimer, Miriam L.
    Nicolle, Michael W.
    Magnus, Tim
    Pulley, Michael T.
    Rivner, Michael
    Dimachkie, Mazen M.
    Distad, B. Jane
    Pascuzzi, Robert M.
    Babiar, Donna
    Lin, Jiang
    Querolt Coll, Montse
    Griffin, Rhonda
    Mondou, Elsa
    [J]. NEUROLOGY, 2023, 100 (07) : E671 - E682
  • [8] PRELIMINARY-RESULTS OF A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF CYCLOSPORINE IN MYASTHENIA-GRAVIS
    TINDALL, RSA
    ROLLINS, JA
    PHILLIPS, JT
    GREENLEE, RG
    WELLS, L
    BELENDIUK, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (12): : 719 - 724
  • [9] Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis ( MycarinG): a randomised, double- blind, placebo- controlled, adaptive phase 3 study (vol 22, pg 383, 2023)
    Bril, V
    Druzdz, A.
    Grosskreutz, J.
    [J]. LANCET NEUROLOGY, 2023, 22 (10): : E11 - E11
  • [10] Efficacy of Rozanolixizumab in Generalized Myasthenia Gravis: Subgroup Analyses from the Randomized Phase 3 MycarinG Study
    Vu, Tuan
    Druzdz, Artur
    Grosskreutz, Julian
    Habib, Ali A.
    Kaminski, Henry J.
    Mantegazza, Renato
    Utsugisawa, Kimiaki
    Vissing, John
    Beau-Lejdstrom, Raphaelle
    Boehnlein, Marion
    Gasalla, Teresa
    Grimson, Fiona
    Tarancon, Thais
    Bril, Vera
    [J]. NEUROLOGY, 2023, 100 (17)